Related Experiment Video

Updated: Sep 29, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.7K

Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World

Matteo Santoni1, Gaetano Aurilio2, Francesco Massari3

  • 1Oncology Unit, Macerata Hospital, Macerata, Italy.

Clinical Genitourinary Cancer
|March 20, 2022
PubMed
Abstract

Insights

Nivolumab and cabozantinib show activity in metastatic renal cell carcinoma (mRCC). Cabozantinib demonstrated significantly longer progression-free survival in clear cell histology and good-risk patients.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Tyrosine-kinase inhibitors (TKIs) are a first-line option for metastatic renal cell carcinoma (mRCC).
  • Real-world data on second-line therapies are crucial for treatment decisions.

Purpose of the Study:

  • To compare the real-world efficacy of nivolumab versus cabozantinib as second-line therapy in mRCC.
  • To analyze treatment outcomes in specific mRCC subpopulations.

Main Methods:

  • Retrospective data collection from 11 centers across Italy, Spain, and the US.
  • Analysis of Overall Survival (OS) and Progression-Free Survival (PFS) using Kaplan-Meier curves and Cox proportional models.

Main Results:

  • Data from 343 mRCC patients (123 cabozantinib, 220 nivolumab).
  • Cabozantinib showed significantly longer PFS in clear cell histology (7.8 vs. 5.4 months, P=0.026) and good-risk patients (12.3 vs. 5.7 months, P=0.022).
  • Trends favored nivolumab in older patients (>70 years) and those with good/intermediate risk, and cabozantinib in patients pre-treated with sunitinib or with bone metastases, though not statistically significant.

Conclusions:

  • Nivolumab and cabozantinib are active agents in mRCC.
  • These therapies demonstrate distinct efficacy profiles when stratified by clinico-pathological features, suggesting personalized treatment approaches.
Keywords:
CabozantinibImmunotherapyNivolumabPrognostic FactorsRenal Cell CarcinomaSurvival

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
699
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
276
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K